Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?

Title: Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?

Volume: 16 Issue: 26

Author(s): Kursat Tigen and Cihan Cevik

Affiliation:

Keywords: Dilated Cardiomyopathy, Beta-blocker Therapy, beta-blockers, heart failure, metoprolol, carvedilol, bisoprolol, Congestive heart failure, angiotensin-converting enzyme, angiotensin receptor blockers, aldos-terone antagonists, left ventricular, arrhythmias, Catecholamines, cardiomyocytes, renin-angiotensin, apoptosis, myocardial fibers is reduced, the sarcoplasmic reticulum, placebo-controlled, receptors, nebivolol, hemodynamics, bradycardia, Atrial fibrillation, sinus rhythm, Peripheral vascular disease, hypoglycemia, glycosylated hemoglobin, chronic obstructive pulmonary disease, bronchospasm

Abstract: Among the multiple pharmacologic and non-pharmacologic therapies, beta-blockers seem to be the mainstay of heart failure management. Although the first large studies failed to demonstrate a significant improvement in mortality, the results from subsequent studies revealed significant risk reductions in mortality with metoprolol, carvedilol and bisoprolol. Decision of the appropriate therapeutic agent depends on the existence of some specific conditions complicating dilated cardiomyopathy. This article reviews the impact of beta-blocker therapy in patients with dilated cardiomyopathy of ischemic or non-ischemic etiology.

Cite this article as:

Tigen Kursat and Cevik Cihan, Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?, Current Pharmaceutical Design 2010; 16 (26) . https://dx.doi.org/10.2174/138161210793176473